Oncocyte to Announce First Quarter 2024 Financial Results
13 Mai 2024 - 2:00PM
Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics
company, announced today that the company will release its first
quarter 2024 financial results on Wednesday, May 15, 2024, after
U.S. market close. The company will host a conference call and
webcast on Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time to
discuss its financial results and highlights.
Interested parties may access the live call via telephone by
dialing toll free (800) 715-9871 for both domestic and
international callers. Once dialed in, ask to be joined to the
Oncocyte Corporation call.
The live webcast of the call may be accessed by visiting the
“Events & Presentations” section of the Company’s website
at https://investors.oncocyte.com. A replay of the webcast
will be available on the Company’s website shortly after the
conclusion of the call.
CONFERENCE CALL DETAILSParticipant Toll-Free
Dial-In Number: (800) 715-9871Participant Toll Dial-In Number: +1
(646) 307-1963Conference ID: 4153469
Webcasthttps://events.q4inc.com/attendee/796340413
About Oncocyte
Oncocyte is a precision diagnostics company. The Company’s tests
are designed to help provide clarity and confidence to physicians
and their patients. VitaGraft™ is a clinical blood-based solid
organ transplantation monitoring test, GraftAssure™ is a research
use only blood-based solid organ transplantation monitoring test,
DetermaIO™ is a gene expression test that assesses the tumor
microenvironment to predict response to immunotherapies, and the
pipeline test DetermaCNI™ is a blood-based monitoring tool for
monitoring therapeutic efficacy in cancer patients. For more
information, visit https://oncocyte.com/
VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are
trademarks of Oncocyte Corporation.
Contact:Jeff RamsonPCG Advisory(646)
863-6893jramson@pcgadvisory.com
Oncocyte (NASDAQ:OCX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Oncocyte (NASDAQ:OCX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024